- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04657887
Registry of Patients With Von WilLEbrand Disease Treated With Voncento® (OPALE)
April 18, 2024 updated by: CSL Behring
Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after patient inclusion.
Study Overview
Detailed Description
Inherited von Willebrand disease (VWD) is considered the most common bleeding disorder.
Its prevalence is approximately 1% in the general population but symptomatic patients are rarer (0.01%).
It is caused by a partial or total quantitative deficiency (type 1 and type 3) or by a qualitative defect (type 2) of von Willebrand factor (VWF), a large multimeric protein that is required for platelet adhesion and serves as factor VIII (FVIII) carrier.
Type 2 VWD is further divided in four subgroups (2A, 2B, 2M, and 2N) that are distinguished according to the nature of the VWF defect.
Most patients with type 1 VWD can be treated with the synthetic vasopressin analogue desmopressin (DDAVP; 2-desamino-8-D-arginine vasopressin), whereas patients with type 3 VWD and most patients with type 2 VWD require concentrates containing VWF. Plasma-derived FVIII concentrates, which were initially developed for the treatment of haemophilia, contain large amounts of VWF and are used in patients for whom DDAVP treatment is deemed ineffective or contraindicated.
Voncento® (CSL Behring) is a plasma-derived FVIII/VWF concentrate registered in France since 2015 for the treatment and prevention of bleeding events in patients with inherited VWD.
OPALE is an observational study describing the use of human coagulation FVIII/VWF concentrate (Voncento®) to treat and prevent bleeding episodes in a French cohort of patients with inherited von Willebrand disease in the real life settings.
The aim of the OPALE study is to describe the efficacy and the safety of Voncento® in the prophylaxis and treatment of haemorrhage or surgical bleeding.
Study Type
Observational
Enrollment (Actual)
135
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Besançon, France
- CHU Besançon
-
Bordeaux, France
- CHU Bordeaux
-
Brest, France
- CHU Morvan Brest
-
Bron, France
- CHU Lyon
-
Caen, France
- CHU Caen
-
Eaubonne, France
- Hôpital Simone Veil
-
Le Chesnay, France
- Hôpital Mignot
-
Le Kremlin-Bicêtre, France
- Hôpital Bicêtre
-
Montpellier, France
- Hôpital Saint-Eloi
-
Nancy, France
- CHRU Nancy
-
Nantes, France
- CHU Nantes
-
Paris, France
- Hôpital Cochin
-
Paris, France
- Hôpital Necker
-
Paris, France
- CHU Lariboisière
-
Rennes, France
- CHU Rennes
-
Rouen, France
- CHU Rouen
-
Strasbourg, France
- CHU Strasbourg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
French cohort of patients with inherited von Willebrand disease treated with Voncento.
Description
Inclusion Criteria:
- Patients suffering from constitutional von Willebrand disease for whom Desmopressin treatment is deemed ineffective or contraindicated
- Patients suffering from von Willebrand disease and being treated or having been treated with Voncento® for the treatment of surgical and non-surgical bleeding episodes, the prophylaxis of surgical and non-surgical bleedings
- Patients with no history or suspicion of inhibitors (judged on previous efficacy)
Exclusion Criteria:
- Refusal of the patient or the patient's legal representative to take part in the study;
- Existence of a contraindication to the use of Voncento® treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Global assessment by the patient and the investigator of the hemostatic efficacy of Voncento® in the management of non-surgical bleeding episodes
Time Frame: Up to 24 months
|
Up to 24 months
|
Number of non-surgical bleeding episodes per year
Time Frame: Up to 24 months
|
Up to 24 months
|
Number of administrations of Voncento® needed to treat a non-surgical bleeding episode and for the long term prophylaxis
Time Frame: Up to 24 months
|
Up to 24 months
|
Total dose of Voncento® (in IU/kg of VWF) needed to treat a non-surgical bleeding episode and for the long term prophylaxis
Time Frame: Up to 24 months
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment by the investigator of the hemostatic efficacy of Voncento® during the treatment and the prophylaxis of surgical bleedings and after surgical procedures
Time Frame: Up to 24 months
|
Up to 24 months
|
Number of administrations of Voncento® needed to prevent or treat surgical bleeding episode
Time Frame: Up to 24 months
|
Up to 24 months
|
Total dose of Voncento® (in IU/kg of VWF) needed to prevent or treat surgical bleeding episode
Time Frame: Up to 24 months
|
Up to 24 months
|
Nature and impact of adverse events and in particular serious adverse events, adverse events related to Voncento®
Time Frame: Up to 24 months
|
Up to 24 months
|
Collection of available biological data (ex: FVIII, VWF:Rco, VWF:Ag)
Time Frame: At baseline and up to 24 months
|
At baseline and up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, CSL Behring SA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 23, 2015
Primary Completion (Actual)
December 31, 2023
Study Completion (Actual)
December 31, 2023
Study Registration Dates
First Submitted
December 1, 2020
First Submitted That Met QC Criteria
December 7, 2020
First Posted (Actual)
December 8, 2020
Study Record Updates
Last Update Posted (Actual)
April 19, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPALE study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Von Willebrand Disease
-
University Hospital, CaenRecruitingVon Willebrand Disease, Type 2BFrance
-
Archemix Corp.Withdrawn
-
Baxalta now part of ShireCompletedVon Willebrand DiseaseUnited States, Germany, United Kingdom, Italy, Austria, Canada
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlActive, not recruitingType 3 Von Willebrand's DiseaseFinland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
-
Archemix Corp.CompletedPurpura, Thrombotic Thrombocytopenic | Von Willebrand Disease Type-2bAustria
-
St. James's Hospital, IrelandUnknown
-
TakedaNot yet recruitingVon Willebrand Disease (VWD)
-
Baxalta now part of ShireTakeda Development Center Americas, Inc.RecruitingVon Willebrand Disease (VWD)United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
-
TakedaCompletedVon Willebrand Disease (VWD)Canada
-
TakedaCompletedVon Willebrand Disease (VWD)Germany
Clinical Trials on Voncento®
-
CSL BehringCompletedVon Willebrand DiseasePoland, Germany, Austria, Greece, United Kingdom
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of